These guidelines update the goals of multiple sclerosis treatment and thresholds to switch or stop therapy.
Sponsoring OrganizationThe Guideline Development, Dissemination, and Implementation Subcommittee of the AAN convened a panel of multiple sclerosis (MS) experts. They developed 30 recommendations on the use of disease modifying therapies (DMTs).
Target Population: People with relapsing or progressive forms of MS or clinically isolated syndromes
Background and Objective
Numerous new disease modifying therapies have high efficacy but potentially serious adverse effects. Deciding when to start, switch, or stop these drugs can be challenging.
Key Points
Starting
An office visit is recommended to counsel and discuss the benefits and risks of the medications to prevent relapses and new MRI lesions, considering adherence, comorbidities, and family planni…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)